Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 735 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Cholestasis, Extrahepatic
Interventions: Bile Duct Cannulation; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obstructive Jaundice, Pancreatic Cancer
Interventions: Stent Dysfunction, Complications; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Month to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Sclerosing Cholangitis
Interventions: Seladelpar, Placebo to match Seladelpar; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions: capecitabine, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 251
States / cities: Anniston, Alabama • Little Rock, Arkansas • Berkeley, California + 181 more

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more

Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
Interventions: DKN-01, gemcitabine, cisplatin; Drug
Lead sponsor: Leap Therapeutics, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma
Interventions: Trifluridine/tipiracil, Oxaliplatin; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Elafibranor, Matched 80 mg placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 43
States / cities: Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more

Conditions: Gastro-Intestinal Disorder
Interventions: Evaluate and compare the efficacy of our training within the Fellowship Council curriculums; Behavioral
Lead sponsor: Methodist Health System; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: ixabepilone, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Biliary Cholangitis
Interventions: Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pancreatic Cancer, Biliary Cancer
Interventions: Gemcitabine, 5-FU, Cisplatin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ampullary Cancer, Duodenal Cancer, Bile Duct Cancer, Bile Duct Disorders, Gallstones, Obstructive Jaundice, Pancreatic Disorders (Noncancerous), Colorectal Cancer, Esophageal Cancer, Barrett's Esophagus, Gastric Malignancies, Pancreatic Cancer, Pediatric Gastroenterology, Cholangiocarcinoma, Pancreatic Pseudocysts, Acute and Chronic Pancreatitis, Recurrent Pancreatitis, Cholangitis, Bile Leak, Biliary Strictures, Pancreatic Divisum, Biliary and Pancreatic Stones, Choledocholithiasis
Interventions: Interventional Endoscopy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 295
States / cities: Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more

Conditions: Biliary Tract Neoplasms, Neoplasms, Gastrointestinal Diseases, Digestive System Diseases, Biliary Tract, Stents
Interventions: Evolution® Biliary Stent - Uncovered; Device
Lead sponsor: Cook Group Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Mobile, Alabama • Boca Raton, Florida • Jacksonville, Florida + 5 more

Conditions: Cholecystitis, Acute, Cholecystitis, Chronic
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 90 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Primary Biliary Cirrhosis
Interventions: Genetic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions: ActivSight; Device
Lead sponsor: Activ Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Buffalo, New York • Houston, Texas • Sugar Land, Texas

Conditions: Hepatocellular Carcinoma
Interventions: Erlotinib, Docetaxel; Drug
Lead sponsor: Gabi Chiorean, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Newark, Delaware • Chicago, Illinois • Bloomington, Indiana + 6 more

Conditions: Cancer of the Liver
Interventions: Taxoprexin; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor
Interventions: doxorubicin HCl liposome; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Timeline: Started 1999
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Cholecystitis, Acute
Interventions: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Aurora, Colorado • Atlanta, Georgia • Fort Wayne, Indiana + 3 more

Search by objective public record fields.

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Randomized Trial of Wire and Sphincterotome Systems for Biliary Cannulation

Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression

Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Evaluation of Hepato-Pancreato-Biliary

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Evolution® Biliary Stent System Clinical Study

Study of Pain Perception Between Males and Females Following Laparoscopic Cholecystectomy

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Safety and Feasibility of ActivSightTM in Human

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE